NCT07172802View on ClinicalTrials.gov

A Study of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy in Patients With Advanced or Metastatic Solid Tumors

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

76

Participants

Timeline

Start Date

April 22, 2025

Primary Completion Date

February 28, 2027

Study Completion Date

September 30, 2027

Conditions
Advanced Solid TumorMetastatic Solid TumorNon-small Cell Lung Cancer (NSCLC)Head and Neck (HNSCC)Pancreatic CancerRenal Cell Carcinoma (RCC)
Interventions
DRUG

GI-108

Dose level will be escalated from 0.1mg/kg to 0.6 mg/kg and Recommended phase 2 dose (or RP2D) of GI-108 will be administered via IV infusion Q3W upto 2 years (approximately 35 years)

Trial Locations (3)

03722

RECRUITING

Yonsei University Health System, Severance Hospital, Seoul

05505

RECRUITING

Asan Medical Center, Seoul

06351

RECRUITING

Samsung Medical Center, Seoul

Sponsors
All Listed Sponsors
lead

GI Innovation, Inc.

INDUSTRY

NCT07172802 - A Study of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy in Patients With Advanced or Metastatic Solid Tumors | Biotech Hunter | Biotech Hunter